Other Information

About S-1

A member of the fluoropyrimidine class of chemotherapeutic agents, S-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CDHP), which decreases the degradation of 5-FU in the liver; and oteracil potassium (Oxo), which decreases 5-FU phosphorylation in the gastrointestinal tract. Developed as a gastric cancer treatment, 

• S-1 was first approved in Japan in 1999 and has become a standard of care for the treatment.

  • gastric cancer. 

• S-1 was subsequently approved in Japan for six additional indications: for the treatment.

  • colorectal.

  • head and neck.

  • non-small cell lung.

  • inoperable or recurrent breast.

  • pancreatic.

  • biliary tract cancers. 

• S-1 is also approved for patients with gastric cancer in more than 7 countries and regions in Asia, and in 15 European countries. 

• See more